Compare McCormick & Company, Incorporated (MKC) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McCormick & Company, Incorporated vs Vertex Pharmaceuticals Incorporated — how do they compare? McCormick & Company, Incorporated trades at $51.43 (market cap $13.96B), while Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 9.6× McCormick & Company, Incorporated's market cap, and McCormick & Company, Incorporated pays a 3.7% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| MKC | VRTX | |
|---|---|---|
Market Cap | $13.96B | $134.06B |
Sector | Consumer Staples | Health |
52-Week High | $71.65 | $557.96 |
52-Week Low | $45.60 | $376.62 |
Enterprise Value | $18.57B | $128.18B |
Dividend Yield | 3.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McCormick & Company (MKC) trades at $51.90, down 0.35% with a bearish technical signal. The stock shows strong fundamentals with a P/E of 8.64, net income margin of 21.91%, and consistent dividend growth. Recent Q1 2026 earnings beat expectations, while analyst consensus remains mixed with 11 buy, 17 hold, and 2 sell ratings. The pending $65 billion Unilever Foods merger and London listing plans represent significant corporate developments.
MKC presents a compelling value opportunity with attractive valuation metrics and stable profitability. The Unilever merger offers substantial growth potential but carries integration risks. Current technical weakness near support at $50-$51 creates a potential entry point for long-term investors seeking dividend income and merger upside.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
